Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic Sarcoma

This will be a phase II, single arm study of osteosarcoma patients with fully resected pulmonary metastases. The MTD corresponds to the dosage recommendations of the manufacturer of Iscador® P which is licensed in Sweden, New Zealand, South Korea, Germany and Switzerland for the treatment of solid tumors and precancerous lesions. The study population includes patients with relapse of osteosarcoma in the lung following surgical resection of all gross disease (2nd or greater CR). Following completion of final thoracotomy, they will be treated with Iscador® P at concentrations up to the MTD with

Trial Details

NCT ID
NCT05726383
Phase
PHASE2
Sponsor
Hackensack Meridian Health
Status
RECRUITING
Cancer Type
Osteosarcoma Sarcoma
Interventions
  • Iscador*P
Locations (sample)
  • Hackensack, New Jersey, United States|40.88593,-74.04347
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Histologic diagnosis of osteosarcoma.
  • Patients with at least one episode of relapse in the lung (without limitation of number of episodes), following surgical resection of all gross met…
  • Surgical resection of all possible sites of suspected pulmonary metastases in order to achieve a complete remission within 8 weeks prior to study e…
  • Pathological confirmation of metastases from at least one of the resected sites.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Osteosarcoma Sarcoma Trials on Trialify →